Navigation Links
Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
Date:10/19/2008

Non-surgical intervention cures 96% of patients with advanced esophagus

condition

SUNNYVALE, Calif., Oct. 19 /PRNewswire/ -- BARRX Medical, Inc. today announced clinical trial results presented at the United European Gastroenterology Week (UEGW) in Vienna, Austria, October 18-22, 2008. In a plenary presentation entitled, "Stepwise circumferential and focal radiofrequency energy ablation of Barrett's esophagus with early neoplasia: First European Multi-centre trial" patients with the most advanced stages of Barrett's esophagus, dysplasia and early cancer, were staged with endoscopic mucosal resection and then treated with the endoscopic radiofrequency ablation using the HALO Ablation System. After treatment, 96% of patients were cured of all diseased tissue, with average follow-up exceeding one year.

Population-based studies estimate that Barrett's esophagus affects approximately six million European and US adults and is a complication of a disorder called gastroesophageal reflux disease or GERD. Once diagnosed, Barrett's can worsen over time, developing dysplasia and esophageal adenocarcinoma (cancer), as in this study. Once dysplasia or cancer occurs, an esophagectomy (surgical removal of the entire esophagus) has been the first-line therapy. Esophageal cancer of this type is the fastest growing cancer in industrialized countries.

Jacques Bergman, M.D., Associate Professor, Department of Gastroenterology, Academic Medical Centre, Amsterdam, the Netherlands, was the senior investigator for this study. "In several back to back studies now, we have been successful in using the HALO Ablation System in conjunction with endoscopic resection to cure patients with advanced dysplasia or early cancer of the esophagus," says Dr. Bergman. "Until now, these patients would receive an esophagectomy or more invasive endoscopic therapies, which often have associated safety risks. In this study, the complete response rate
'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
4. First European Patients Treated With the Percutaneous MitraClip(R) System
5. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
6. Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
7. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
8. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
9. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
10. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
11. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Dec. 4 Hospira, Inc. (NYSE: HSP ... company, today announced the launch of its next-generation 50 ... medications and solutions, and now offers a complete size ... environmentally responsible VisIV product. The launch of the 50 ...
(Date:12/4/2009)... OrthoAccel Technologies, Inc., developers of the AcceleDent ... enhance orthodontics, announced the availability of a new ... , a leader in professional education for many ... focuses on patient views about orthodontic treatment, a ...
(Date:12/4/2009)... Del., Dec. 4 AstraZeneca (NYSE: AZN ... Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) ... in adults with Major Depressive Disorder (MDD). SEROQUEL XR ... the FDA to treat both major depressive disorder as ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Spherix Announces Positive Phase 2 Study Results 4641 1Spherix Announces Positive Phase 2 Study Results 4641 2Spherix Announces Positive Phase 2 Study Results 4641 3Spherix Announces Positive Phase 2 Study Results 4641 4Spherix Announces Positive Phase 2 Study Results 4641 5Spherix Announces Positive Phase 2 Study Results 4641 6A breath mint made from coffee 3F 8993 1A breath mint made from coffee 3F 8993 2Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies 4640 1Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies 4640 2
(Date:12/5/2009)... , , SATURDAY, Dec. 5 (HealthDay News) -- They,re not ... bad reactions to certain holiday traditions and need to ... to the American College of Allergy, Asthma and Immunology ... may choose to decorate with artificial plants, but both ...
(Date:12/5/2009)... The MAMA campaign is a collaborative effort by ... Midwives Alliance of North America (MANA), Citizens for ... North American Registry of Midwives (NARM), and the ... a recent the efforts of The MAMA Campaign ...
(Date:12/4/2009)... employees came together in more than 90 offices nationwide today, ... audit, tax and advisory firm,s support for literacy with charitable ... long history of volunteerism. Instead of holiday parties, our employees ... for some children," said Tim Flynn, Chairman of KPMG. ...
(Date:12/4/2009)... Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, ... purchase and sale agreement to acquire a three building ... Texas, and Fort Wayne, Indiana for approximately $20,500,000. ... satisfaction of a number of conditions. ,, The approximately ...
(Date:12/4/2009)... While Congress debates whether health care reform would ... to 45 hospitals that lead through example -- ... while attaining the highest levels of efficiency. Thirty-four ... been named 2009 Leapfrog Top Hospitals, based on ...
Breaking Medicine News(10 mins):Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3
... with multiple sclerosis, according to a new study published ... to soothe nausea and to stimulate appetite.// Researchers evaluated ... multiple sclerosis. ,24 patients with multiple sclerosis and ... were given up to 10 milligrams of dronabinol or ...
... results for the long-term efficacy of a meningitis C ... when given to infants older than 5 months.// ... United Kingdom in 1999. While the short-term effectiveness was ... study looking at the data from the four years ...
... the commonest cancer effecting men. Benefits of Lycophene- an ... pink grapefruit( most lycopene in processed //tomato products including ... in preventing the aging process and improve skin ... being looked at for preventing and treating cancers such ...
... on active baby boomers. Arthritis followed by knee replacement surgery ... middle-aged Americans. Now a new technique offers hope for active ... feet, crouching and clicking, kneeling and directing. His glamour photography ... lifeblood," he says. "If they don't work, I don't work." ...
... shows patients who undergo chemotherapy or radiation expect a high ... chemotherapy or radiation can diminish the quality of life ... such as nausea, he or she is more likely to ... background, and the type of cancer influence how many side ...
... new study which focused on depression in elderly people living ... homes found that // depression and its symptoms have been ... ,The study, involved 250 participants in a community health program. ... of depression and then did so again at 18 months. ...
Other Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: